L-Serine Treatment is Associated with Improvements in Behavior, EEG, and Seizure Frequency in Individuals with GRIN-Related Disorders Due to Null Variants
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Pathogenic missense variants in GRIN2A and GRIN2B may result in gain or loss of function (GoF/LoF) of the N-methyl-D-aspartate receptor (NMDAR). This observation gave rise to the hypothesis of successfully treating GRIN-related disorders due to LoF variants with co-agonists of the NMDAR. In this respect, we describe a retrospectively collected series of ten individuals with GRIN2A- or GRIN2B-related disorders who were treated with L-serine, each within an independent n-of-1 trial. Our cohort comprises one individual with a LoF missense variant with clinical improvements confirming the above hypothesis and replicating a previous n-of-1 trial. A second individual with a GoF missense variant was erroneously treated with L-serine and experienced immediate temporary behavioral deterioration further supporting the supposed functional pathomechanism. Eight additional individuals with null variants (that had been interpreted as loss-of-function variants despite not being missense) again showed clinical improvements. Among all nine individuals with LoF missense or null variants, L-serine treatment was associated with improvements in behavior in eight (89%), in development in four (44%), and/or in EEG or seizure frequency in four (44%). None of these nine individuals experienced side effects or adverse findings in the context of L-serine treatment. In summary, we describe the first evidence that L-serine treatment may not only be associated with clinical improvements in GRIN-related disorders due to LoF missense but particularly also null variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 1×
“3), according to the guidelines of the American College of Medical Genetics and Genomics [12].”
Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2017) · Epilepsia · doi:10.1111/epi.13709 · Cited by 5,054
Vineland Adaptive Behavior Scales, Second Edition
Sparrow, S. S., Cicchetti, D., & Balla, D. A. (2012) · PsycTESTS Dataset · doi:10.1037/t15164-000 · Cited by 978
Hamdan, F. F., Gauthier, J., Araki, Y., Lin, D.-T., Yoshizawa, Y., Higashi, K., Park, A.-R., Spiegelman, D., Dobrzeniecka, S., Piton, A., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.02.001 · Cited by 349
GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine
Pierson, T. M., Yuan, H., Marsh, E. D., Fuentes‐Fajardo, K., Adams, D. R., Markello, T., Golas, G., Simeonov, D. R., Holloman, C., Tankovic, A., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.39 · Cited by 298
Platzer, K., Yuan, H., Schütz, H., Winschel, A., Chen, W., Hu, C., Kusumoto, H., Heyne, H. O., Helbig, K. L., Tang, S., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104509 · Cited by 252 · cited 2×
“In line with this observation, carriers of GRIN2A or GRIN2B null variants tend to display a milder phenotypic spectrum compared to carriers of missense variants [1, 2].”
BackgroundSelf-citationGRIN2A -related disorders: genotype and functional consequence predict phenotype
Strehlow, V., Heyne, H. O., Vlaskamp, D. R. M., Marwick, K. F. M., Rudolf, G., de Bellescize, J., Biskup, S., Brilstra, E. H., Brouwer, O. F., Callenbach, P. M. C., et al. (2019) · Brain · doi:10.1093/brain/awy304 · Cited by 220 · cited 2×
“In line with this observation, carriers of GRIN2A or GRIN2B null variants tend to display a milder phenotypic spectrum compared to carriers of missense variants [1, 2].”
BackgroundSelf-citationDelineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy
Lemke, J. R., Geider, K., Helbig, K. L., Heyne, H. O., Schütz, H., Hentschel, J., Courage, C., Depienne, C., Nava, C., Heron, D., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002740 · Cited by 200
Self-citationSwanger, S. A., Chen, W., Wells, G., Burger, P. B., Tankovic, A., Bhattacharya, S., Strong, K. L., Hu, C., Kusumoto, H., Zhang, J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.10.002 · Cited by 178 · cited 2×
“Functional studies have shown that pathogenic missense variants can result in a gain or loss of NMDAR function or in mixed and more complex functional consequences [6].”
BackgroundLi, D., Yuan, H., Ortiz-Gonzalez, X. R., Marsh, E. D., Tian, L., McCormick, E. M., Kosobucki, G. J., Chen, W., Schulien, A. J., Chiavacci, R., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.07.013 · Cited by 177
Self-citationMetabolism of the neuromodulator d-serine
Pollegioni, L., & Sacchi, S. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0307-9 · Cited by 138 · cited 2×
“Within our international network of collaborators, we have collected standardized information from individuals with GRIN-related disorders that had undergone targeted treatment with the orally available non-essential amino acid L-serine, which mediates co-agonistic effects on the NMDAR in neurons via its enantiomer D-…”
BackgroundTreatment Responsiveness in KCNT1-Related Epilepsy
Fitzgerald, M. P., Fiannacca, M., Smith, D. M., Gertler, T. S., Gunning, B. W., Syrbe, S., Verbeek, N. E., Stamberger, H., Weckhuysen, S., Ceulemans, B., et al. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00739-y · Cited by 108 · cited 1×
“Similar to other observational studies of precision medicine approaches in genetic disorders, such as quinidine treatment in KCNT1-related epilepsy [10], these n-of-1 trials have inspired treatment of several individuals with GRINrelated disorders.”
ResultSelf-citationWechsler Intelligence Scale for Children-V: Test Review
Na, S. D., & Burns, T. G. (2016) · Applied Neuropsychology: Child · doi:10.1080/21622965.2015.1015337 · Cited by 84 · cited 1×
“Different neurodevelopmental tests were performed in 8/10 cases, including Snijders-Oomen non-verbale intelligence test (SON-R) in three individuals, the Bayley Scales of Infant Development Third Edition (Bayley-III) [14] in two individuals, and the Vineland Adaptative Behavior Scales II (VABS-II) [15], the gross moto…”
MethodSoto, D., Olivella, M., Grau, C., Armstrong, J., Alcon, C., Gasull, X., Santos-Gómez, A., Locubiche, S., Gómez de Salazar, M., García-Díaz, R., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw0936 · Cited by 82 · cited 9×
“L-serine treatment started in 2019 even before the initial publication [8] and is still ongoing.”
BackgroundResultInfluentialModelling and treating GRIN2A developmental and epileptic encephalopathy in mice
Amador, A., Bostick, C. D., Olson, H., Peters, J., Camp, C. R., Krizay, D., Chen, W., Han, W., Tang, W., Kanber, A., et al. (2020) · Brain · doi:10.1093/brain/awaa147 · Cited by 78
The Depressive Cognition Scale: Further Psychometric Evaluation
Zauszniewski, J. A. (1997) · Journal of Nursing Measurement · doi:10.1891/1061-3749.5.2.191 · Cited by 40 · cited 1×
“Different neurodevelopmental tests were performed in 8/10 cases, including Snijders-Oomen non-verbale intelligence test (SON-R) in three individuals, the Bayley Scales of Infant Development Third Edition (Bayley-III) [14] in two individuals, and the Vineland Adaptative Behavior Scales II (VABS-II) [15], the gross moto…”
MethodKellner, S., Abbasi, A., Carmi, I., Heinrich, R., Garin-Shkolnik, T., Hershkovitz, T., Giladi, M., Haitin, Y., Johannesen, K. M., Møller, R. S., et al. (2021) · eLife · doi:10.7554/elife.67555 · Cited by 20
Self-citation
Research works printed but not linked: 4
- Benson JB. Language, memory, and cognition in infancy and early childhood. 1. Aufl. s.l.: Elsevier professional, 2009. Available from: http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10343066. Accessed 1 Feb 2020.
- Gross motor function measure (GMFM-66 & GMFM-88) user's manual. Clinics in Developmental Medicine No. 159, By Dianne J Russell, Peter L Rosenbaum, Lisa, 2003. Available from: https://www.cambridge.org/core/journals/developmental-medicine-and-child-neurology/article/gross-motor-function-measure-gmfm66-gmfm88-users-manual-clinics-in-developmental-medicine-no-159-by-dianne-j-russell-peter-l-rosenbaum-lisa-m-avery-mary-lane-london-mac-keith-press-2002-pp-233-5500-us8000-isbn-1-89868329-8-hardback/600f436e66a0a12ebf73c41fa46a5951. Accessed 1 Feb 2020.
- Law MC, Baptiste S, Carswell A. COPM: Canadian Occupational Performance Measure. 5th edition. Idstein: Schulz-Kirchner Verlag; 2017. (Edition Vita Activa Wissenschaftliche Reihe Assessments).
- Fox-Boyer AV. TROG-D: Test zur Überprüfung des Grammatikverständnisses. 7. Auflage. Idstein: Schulz-Kirchner Verlag; 2016. (Edition Steiner im Schulz-Kirchner Verlag).
Cited by
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“…and GRIN2A , an n -of-1 trial (single-patient crossover study) 90 of l-serine, an essential amino acid which is a co-agonist of NMDARs, was effective for seizures in four of nine patients, but caused behavioural deterioration in a child with a GOF variant who was inadvertently treated 91,92 .”
Current practice in diagnostic genetic testing of the epilepsies
Krey, I., Platzer, K., Esterhuizen, A. I., Berkovic, S. F., Helbig, I., Hildebrand, M. S., Lerche, H., Lowenstein, D. H., Møller, R. S., Poduri, A., et al. (2022) · Epileptic Disorders · doi:10.1684/epd.2022.1448 · Cited by 127
Self-citationSerine signaling governs metabolic homeostasis and health
He, L., Ding, Y., Zhou, X., Li, T., & Yin, Y. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.03.001 · Cited by 106
GRIN2B-related neurodevelopmental disorder: current understanding of pathophysiological mechanisms
Sabo, S. L., Lahr, J. M., Offer, M., Weekes, A. L., & Sceniak, M. P. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.1090865 · Cited by 78
“Another article reported that after 2 years of L-serine treatment (∼600 mg/kg), a patient with a an LoF GRIN2B variant displayed improvement in behavioral and cognitive symptoms (Krey et al., 2022).”
BackgroundMethodHerzog, L. E., Wang, L., Yu, E., Choi, S., Farsi, Z., Song, B. J., Pan, J. Q., & Sheng, M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02393-7 · Cited by 66
Metadata
- Authors
- Krey, I., von Spiczak, S., Johannesen, K. M., Hikel, C., Kurlemann, G., Muhle, H., Beysen, D., Dietel, T., Møller, R. S., Lemke, J. R., & Syrbe, S.
- Affiliations
- University Hospital Leipzig (DE)
- University of Southern Denmark (DK)
- St. Bonifatius Hospital (DE)
- University Hospital Schleswig-Holstein (DE)
- Antwerp University Hospital (BE)
- University of Freiburg (DE)
- University Hospital Heidelberg (DE)
- Corresponding author
- Krey, Ilona
- Johannesen, Kathrine M.
- Hikel, Christiane
- Kurlemann, Gerhard
- Muhle, Hiltrud
- Beysen, Diane
- Møller, Rikke S.
- Lemke, Johannes R.
- Syrbe, Steffen
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 19
- Issue
- 1
- Pages
- 334-341
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC9130352
- OpenAlex
- W4205991532
- Cited by
- 48
- References
- 17
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 14 · 2023: 11 · 2022: 6
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6 d)
- Locations
- Neurotherapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
- Funders
- Dietmar Hopp Stiftung (1DH1813319)
- Otfried-Förster-Stipendium
- Universitätsklinikum Leipzig
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- L-serine, GRIN2A, NR2B subunit, NMDA receptor, null variants, loss-of-function mutations, gain-of-function mutations, missense mutations, seizure frequency, EEG, behavior improvement, developmental outcomes, N-of-1 trials
- MeSH terms
- Electroencephalography, Humans, Retrospective Studies, Seizures, Serine, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.